Peeling Back The Layers: Exploring Sage Therapeutics Through Analyst Insights
Portfolio Pulse from Benzinga Insights
Sage Therapeutics (NASDAQ:SAGE) has been rated by 5 analysts in the last three months, all maintaining an indifferent stance. The 12-month price targets show an average of $23.4, up 6.36% from the previous $22.00. The company's financial performance indicates a significant revenue growth of 2621.54% over 3 months, with a market capitalization above industry average, a net margin of -41.95%, an ROE of -4.05%, and an ROA of -3.57%. Its debt-to-equity ratio is low at 0.01.
February 28, 2024 | 8:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Sage Therapeutics has received consistent indifferent ratings from analysts, with an updated average price target of $23.4. The company's financials show substantial revenue growth and strong performance metrics.
The unanimous indifferent stance from analysts, combined with a significant revenue growth and strong financial performance indicators such as ROE and ROA, suggest a positive outlook for SAGE in the short term. The increase in the average price target further supports this optimism.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100